{"id":"NCT01705574","sponsor":"Gilead Sciences","briefTitle":"Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women","officialTitle":"A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10-24","primaryCompletion":"2015-02-09","completion":"2018-09-06","firstPosted":"2012-10-12","resultsPosted":"2016-03-10","lastUpdate":"2019-09-20"},"enrollment":583,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Acquired Immunodeficiency Syndrome","HIV Infections"],"interventions":[{"type":"DRUG","name":"E/C/F/TDF","otherNames":["Stribild®"]},{"type":"DRUG","name":"ATV","otherNames":["Reyataz®"]},{"type":"DRUG","name":"RTV","otherNames":["Norvir®"]},{"type":"DRUG","name":"FTC/TDF","otherNames":["Truvada®"]},{"type":"DRUG","name":"E/C/F/TDF Placebo","otherNames":[]},{"type":"DRUG","name":"ATV Placebo","otherNames":[]},{"type":"DRUG","name":"RTV Placebo","otherNames":[]},{"type":"DRUG","name":"FTC/TDF Placebo","otherNames":[]},{"type":"DRUG","name":"E/C/F/TAF","otherNames":["Genvoya®"]}],"arms":[{"label":"E/C/F/TDF","type":"EXPERIMENTAL"},{"label":"ATV + RTV+ FTC/TDF","type":"ACTIVE_COMPARATOR"},{"label":"Open-Label Extension Phase","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the efficacy of a regimen containing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) versus ritonavir (RTV)-boosted atazanavir (ATV/r) plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in HIV-1 infected, antiretroviral treatment-naive adult women.","primaryOutcome":{"measure":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 of the Double-Blind Phase as Determined by the US FDA-Defined Snapshot Algorithm","timeFrame":"Week 48","effectByArm":[{"arm":"Double-Blind STB","deltaMin":87.2,"sd":null},{"arm":"Double-Blind ATV+RTV+TVD","deltaMin":80.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":"0.034"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":13},"locations":{"siteCount":99,"countries":["United States","Belgium","Dominican Republic","France","Italy","Mexico","Portugal","Puerto Rico","Russia","Thailand","Uganda","United Kingdom"]},"refs":{"pmids":["27562742"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":25,"n":289},"commonTop":["Upper respiratory tract infection","Headache","Nausea","Malaria","Neuropathy peripheral"]}}